-
Neratinib (INN), sold
under the
brand name Nerlynx, is a
tyrosine kinase inhibitor anti-cancer
medication used for the
treatment of
breast cancer. The...
- in 2010. In
August 2011 Puma
licensed two drug
candidates from Pfizer:
neratinib (PB272) and an
analog (PB357) to
serve as a
backup candidate.: 6, 23 ...
- afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib,
neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib...
- 1-1% frequency)
Keratitis Interstitial lung
disease Like
lapatinib and
neratinib,
afatinib is a
protein kinase inhibitor that also
irreversibly inhibits...
-
expected to lead to a
wider therapeutic index. The pan-ErbB
inhibitor Neratinib was
approved in the US in 2017 and in the EU in 2018 for the extended...
- first-generation inhibitors,
researchers have used
irreversible EGFR
inhibitors like
neratinib or dacomitinib,
called tyrosine kinase inhibitors (TKIs).
These new drugs...
-
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies:
Cetuximab Depatuxizumab Depatuxizumab...
- co-opted to
promote cancer cell
survival and metastasis. In
breast cancers,
neratinib, a
novel pan-ERBB inhibitor, is able to
downmodulate the
amount of HER2...
-
margetuximab can also
prolong survival, as can HER2
inhibitors lapatinib,
neratinib, or tucatinib.
Certain therapies are
targeted at
those whose tumors have...
-
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies:
Cetuximab Depatuxizumab Depatuxizumab...
